Low microRNA-133a level in gastric juice forebodes unfavorable progression and prognosis of gastric cancer

SHAO Juan KONG Gui-mei SHI Ming-yi BO Ping*

doi:10.16098/j.issn.0529-1356.2017.05.009

PDF(596 KB)

Acta Anatomica Sinica ›› 2017, Vol. 48 ›› Issue (5) : 550-555. DOI: 10.16098/j.issn.0529-1356.2017.05.009

Cancer Biology

Low microRNA-133a level in gastric juice forebodes unfavorable progression and prognosis of gastric cancer

SHAO Juan^1,2 KONG Gui-mei¹SHI Ming-yi¹ BO Ping^1*

Author information +

History +

Abstract

Objective We previously reported that the microRNA-133a (MiR-133a) levels in gastric juice and carcinoma tissues of patients with gastric cancer were significantly down-regulated, the current research surveyed whether low MiR-133a levels in gastric juice are related to the progression and prognosis of gastric cancer. Methods The gastric juice and mucosa samples were collected from an independent set of 236 masked pattern: 34 from healthy donors and 202 from patients with gastric cancer. In addition, cell invasion and migration abilities were observed with Transwell invasion assay and wound healing migration assay.
Results MiR-133a levels in gastric juice and carcinoma tissues of patients with gastric cancer were significantly downregulated, and associated with advanced tumor grade, T stage and presence of metastasis. MiR-133a significantly inhibited the invasion and migration abilities of gastric cancer cells. The low MiR-133a expression in gastric juice was taken as a poor prognostic marker of both overall and disease-free survival in patients with gastric cancer. Conclusion These findings justify that low MiR-133a expression in gastric juice strongly associates with advanced tumor progression and unfavorable clinical outcome of patients with gastric cancer, and might be used as a useful tool to estimating progression and prognosis of this disease.

Key words

MicroRNA-133a / Gastric juice / Gastric cancer / Transwell test / Scratch test / Human

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

SHAO Juan KONG Gui-mei SHI Ming-yi BO Ping. Low microRNA-133a level in gastric juice forebodes unfavorable progression and prognosis of gastric cancer[J]. Acta Anatomica Sinica. 2017, 48(5): 550-555 https://doi.org/10.16098/j.issn.0529-1356.2017.05.009

References

［1］Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 ［J］. CA Cancer J Clin, 2012,62(1):10-29.

［2］Lin Y, Ueda J, Kikuchi S, et al. Comparative epidemiology of gastric cancer between Japan and China ［J］. World J Gastroenterol, 2011,17(39), 4421-4428.

［3］Sturgeon CM, Duffy MJ, Hofmann BR, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers ［serial online］［J］. Clin Chem, 2010,56(6):e1-e48.

［4］Yamamoto H, Kohashi K, Fujita A, et al. Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromaltumor ［J］. Mod Pathol,2013,26(4):563-571.

［5］Xu XC, Zhang YH, Zhang WB, et al. MicroRNA-133a functions as a tumor suppressor in gastric cancer ［J］. J Biol Regul Homeost Agents, 2014,28(4):615-624.

［6］Wu WK, Lee CW, Cho CH, et al. MicroRNA dysregulation in gastric cancer: a new player enters the game ［J］. Oncogene, 2010,29(43), 5761-5771.

［7］Qiu T, Zhou X, Wang J, et al. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer ［J］. FEBS Lett, 2014,588(7):1168-1177.

［8］Zhou Y, Wu D, Tao J, et al. MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer ［J］. Scandinavian J Urol, 2013, 47(5): 423-432.

［9］Tucci A, Bisceglia M, Rugge M, et al. Clinical usefulness of gastric-juice analysis in 2007: the stone that the builders rejected has become the cornerstone ［J］. Gastrointest Endosc, 2007,66(5): 881-890.

［10］Yamasaki T, Yoshino H, Enokida H, et al. Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer ［J］. Int J Oncol, 2012, 40(6): 1821-1830.

［11］Zhang X, Cui L, Ye G, et al. Gastric juice microRNA-421 is a new biomarker for screening gastric cancer ［J］. Tumour Biol, 2012,33(6): 2349-2355.

［12］Kinoshita T, Hanazawa T, Nohata N, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma ［J］. Oncotarget, 2012, 3(11): 1386-1400.

［13］Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection ［J］. Clin Cancer Res, 2009,15(17):5473-5477.

［14］Chen X, Liang H, Zhang J, et al. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications ［J］. Protein Cell, 2012,3(1):28-37.

［15］Ohshima K, Inoue K, Fujiwara A, et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line ［serial online］［J］. PLoS One, 2010,5(10):e13247.

［16］Qiu T, Zhou X, Wang J, et al. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer ［J］. FEBS Lett, 2014, 588(7): 1168-1177.

［17］Gong Y, Ren J, Liu K, et al. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R ［J］. World J Gastroenterol, 2015, 21(10): 2949-2958.

［18］Chen WS, Leung CM, Pan HW, et al. Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer ［J］. Oncol Rep, 2012, 28(3):1069-1076.

［19］Tucci A, Bisceglia M, Rugge M, et al. Clinical usefulness of gastric-juice analysis in 2007: the stone that the builders rejected has become the cornerstone ［J］. Gastrointest Endosc, 2007, 66(5):881-890.

［20］Shao J, Fang PH, He B, et al. Downregulated MicroRNA-133a in gastric juice as a clinicopathological biomarker for gastric cancer screening ［J］. Asian Pac J Cancer Prev, 2016,17(5):2719-2722.